RECRUITING

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

Description

The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic dermatitis (AD).

Conditions

Atopic Dermatitis
Talk to us

Related Conditions:

Atopic Dermatitis

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic dermatitis (AD).

A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of RO7790121 in Patients With Moderate to Severe Atopic Dermatitis

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

Condition
Atopic Dermatitis
Intervention / Treatment

-

Contacts and Locations

Los Angeles

Dermatology Research Associate, Los Angeles, California, United States, 90045

Miami

Suncoast Research Associates LLC - ERN - PPDS, Miami, Florida, United States, 33173

Tampa

Olympian Clinical Research, Tampa, Florida, United States, 33615

Alpharetta

Hamilton Research, LLC, Alpharetta, Georgia, United States, 30022

Atlanta

Dermatology Affiliates Research Institute, LLC, Atlanta, Georgia, United States, 30305

Indianapolis

Dawes Fretzin Clinical Res LLC, Indianapolis, Indiana, United States, 46250

Troy

Revival Research Institute, LLC, Troy, Michigan, United States, 48084

Hoboken

Care Access Research - Hoboken, Hoboken, New Jersey, United States, 07030

Dublin

Centricity Research Dublin, Dublin, Ohio, United States, 43016

Camp Hill

Best Skin Research LLC, Camp Hill, Pennsylvania, United States, 17011

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * AD diagnosis confirmed by a dermatologist according to the Hanifin/Rajka criteria at least 1 year prior to screening
  • * Moderate to severe AD
  • * At least once daily use of an additive-free, bland emollient for at least 7 days prior to the baseline visit and during the study
  • * Evidence of other skin conditions that would interfere with the assessment of AD, including, but not limited to, for example cutaneous T-cell lymphoma, allergic contact dermatitis
  • * IV, IM, IL, and oral corticosteroids (inhaled, ophthalmic drops, and nasal corticosteroids are allowed) within 4 weeks of the baseline visit and during the study
  • * Topical treatment for AD including, but not limited to topical corticosteroids, topical calcineurin Inhibitors, topical PDE-4 inhibitors, , prescription moisturizers or moisturizers containing additives such as ceramide, hyaluronic acid, urea or filaggrin within 7 days prior to the baseline visit and during the study
  • * Any active infection or other active skin diseases that required treatment with parenteral anti-infectives within 4 weeks or oral anti-infective treatment within 2 weeks prior to baseline
  • * Acquired or congenital immunodeficiency
  • * Systemic therapies that are also used in the treatment of AD, including, but not limited to methotrexate, cyclosporine, azathioprine, mycophenolate mofetil within 4 weeks of the baseline visit and during the study

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Hoffmann-La Roche,

Clinical Trials, STUDY_DIRECTOR, Hoffmann-La Roche

Study Record Dates

2026-11-26